Tags

Type your tag names separated by a space and hit enter

Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone.
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27; 37(1):128-31.PN

Abstract

BACKGROUND

Subjects with Pervasive Developmental Disorders (PDD) often exhibit behavioral symptoms such as aggressiveness and irritability, which are targets of psychopharmacologic intervention. This retrospective study was designed to examine children and adolescents with PDD experiencing tolerability issues with risperidone treatment, and thereby assess the efficacy and tolerability of switching to aripiprazole.

METHODS

This naturalistic study included 23 subjects with PDD (16 males, 7 females, age range 9-24 years, mean age 15.1±3.9 years) diagnosed according to DSM-IV criteria and followed up for 14.9±8.4 weeks after switching to aripiprazole from risperidone. Outcome measures were the Clinical Global Impression-Severity (CGI-S) and CGI Improvement (CGI-I) scales.

RESULTS

The mean CGI-S scores of pre-aripiprazole treatment and post-aripiprazole treatment were, respectively 4.7±1.4 and 4.6±1.3. Mean maintenance dosages of risperidone and aripiprazole were, respectively, 0.7±0.5mg/day and 2.8±1.3mg/day. The mean CGI-I score, which shows the difference induced by switching from risperidone to aripiprazole, was 3.4±0.8 for the whole sample, suggesting that the efficacy of risperidone for treating behavioral problems of PDD was maintained by aripiprazole. Some improvement of safety/tolerability issues such as increased appetite, somnolence, hyperprolactinemia, and amenorrhea occurred after switching to aripiprazole.

CONCLUSION

Results show that switching to aripiprazole might be generally well tolerated and might constitute an alternative treatment for subjects with PDD who experience tolerability issues with risperidone treatment. Additional long-term controlled studies of PDD subjects should be undertaken to evaluate the efficacy and safety of switching to aripiprazole from other antipsychotics.

Authors+Show Affiliations

Department of Neuropsychiatry, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-Cho, Yoshida-Gun, Fukui 910-1193, Japan. mak1977019@yahoo.co.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

22245026

Citation

Ishitobi, Makoto, et al. "Switching to Aripiprazole in Subjects With Pervasive Developmental Disorders Showing Tolerability Issues With Risperidone." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 37, no. 1, 2012, pp. 128-31.
Ishitobi M, Hiratani M, Kosaka H, et al. Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):128-31.
Ishitobi, M., Hiratani, M., Kosaka, H., Takahashi, T., Mizuno, T., Asano, M., Murata, T., Tomoda, A., & Wada, Y. (2012). Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone. Progress in Neuro-psychopharmacology & Biological Psychiatry, 37(1), 128-31. https://doi.org/10.1016/j.pnpbp.2011.12.015
Ishitobi M, et al. Switching to Aripiprazole in Subjects With Pervasive Developmental Disorders Showing Tolerability Issues With Risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):128-31. PubMed PMID: 22245026.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone. AU - Ishitobi,Makoto, AU - Hiratani,Michio, AU - Kosaka,Hirotaka, AU - Takahashi,Tetsuya, AU - Mizuno,Tomoyuki, AU - Asano,Mizuki, AU - Murata,Tetsuhito, AU - Tomoda,Akemi, AU - Wada,Yuji, Y1 - 2012/01/08/ PY - 2011/10/17/received PY - 2011/12/12/revised PY - 2011/12/29/accepted PY - 2012/1/17/entrez PY - 2012/1/17/pubmed PY - 2012/11/9/medline SP - 128 EP - 31 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog. Neuropsychopharmacol. Biol. Psychiatry VL - 37 IS - 1 N2 - BACKGROUND: Subjects with Pervasive Developmental Disorders (PDD) often exhibit behavioral symptoms such as aggressiveness and irritability, which are targets of psychopharmacologic intervention. This retrospective study was designed to examine children and adolescents with PDD experiencing tolerability issues with risperidone treatment, and thereby assess the efficacy and tolerability of switching to aripiprazole. METHODS: This naturalistic study included 23 subjects with PDD (16 males, 7 females, age range 9-24 years, mean age 15.1±3.9 years) diagnosed according to DSM-IV criteria and followed up for 14.9±8.4 weeks after switching to aripiprazole from risperidone. Outcome measures were the Clinical Global Impression-Severity (CGI-S) and CGI Improvement (CGI-I) scales. RESULTS: The mean CGI-S scores of pre-aripiprazole treatment and post-aripiprazole treatment were, respectively 4.7±1.4 and 4.6±1.3. Mean maintenance dosages of risperidone and aripiprazole were, respectively, 0.7±0.5mg/day and 2.8±1.3mg/day. The mean CGI-I score, which shows the difference induced by switching from risperidone to aripiprazole, was 3.4±0.8 for the whole sample, suggesting that the efficacy of risperidone for treating behavioral problems of PDD was maintained by aripiprazole. Some improvement of safety/tolerability issues such as increased appetite, somnolence, hyperprolactinemia, and amenorrhea occurred after switching to aripiprazole. CONCLUSION: Results show that switching to aripiprazole might be generally well tolerated and might constitute an alternative treatment for subjects with PDD who experience tolerability issues with risperidone treatment. Additional long-term controlled studies of PDD subjects should be undertaken to evaluate the efficacy and safety of switching to aripiprazole from other antipsychotics. SN - 1878-4216 UR - https://www.unboundmedicine.com/medline/citation/22245026/Switching_to_aripiprazole_in_subjects_with_pervasive_developmental_disorders_showing_tolerability_issues_with_risperidone_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0278-5846(12)00002-4 DB - PRIME DP - Unbound Medicine ER -